Novo Nordisk A/S (NYSE:NVO) Shares Purchased by Guild Investment Management Inc.

Guild Investment Management Inc. increased its position in shares of Novo Nordisk A/S (NYSE:NVO - Free Report) by 27.9% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 32,953 shares of the company's stock after acquiring an additional 7,191 shares during the period. Novo Nordisk A/S makes up about 3.1% of Guild Investment Management Inc.'s investment portfolio, making the stock its 12th largest position. Guild Investment Management Inc.'s holdings in Novo Nordisk A/S were worth $2,835,000 at the end of the most recent quarter.

A number of other hedge funds have also recently bought and sold shares of the company. Prosperity Wealth Management Inc. boosted its position in shares of Novo Nordisk A/S by 13.5% in the 4th quarter. Prosperity Wealth Management Inc. now owns 8,628 shares of the company's stock valued at $742,000 after purchasing an additional 1,026 shares during the period. Cascade Financial Partners LLC boosted its position in shares of Novo Nordisk A/S by 15.4% in the 4th quarter. Cascade Financial Partners LLC now owns 3,005 shares of the company's stock valued at $258,000 after purchasing an additional 400 shares during the period. Natural Investments LLC acquired a new position in shares of Novo Nordisk A/S in the 4th quarter valued at $1,345,000. Gables Capital Management Inc. boosted its position in shares of Novo Nordisk A/S by 111.1% in the 4th quarter. Gables Capital Management Inc. now owns 1,900 shares of the company's stock valued at $163,000 after purchasing an additional 1,000 shares during the period. Finally, Dearborn Partners LLC boosted its position in shares of Novo Nordisk A/S by 11.2% in the 4th quarter. Dearborn Partners LLC now owns 3,972 shares of the company's stock valued at $342,000 after purchasing an additional 400 shares during the period. 11.54% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

NVO has been the subject of a number of research reports. UBS Group upgraded Novo Nordisk A/S from a "sell" rating to a "buy" rating in a research report on Wednesday, January 8th. StockNews.com lowered Novo Nordisk A/S from a "strong-buy" rating to a "buy" rating in a research report on Sunday, December 29th. BNP Paribas upgraded Novo Nordisk A/S to a "strong-buy" rating in a research report on Monday, December 2nd. Morgan Stanley assumed coverage on Novo Nordisk A/S in a research report on Wednesday, February 12th. They set an "equal weight" rating for the company. Finally, Sanford C. Bernstein upgraded Novo Nordisk A/S from an "underperform" rating to a "market perform" rating in a report on Monday, January 6th. Three equities research analysts have rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, Novo Nordisk A/S presently has a consensus rating of "Moderate Buy" and an average price target of $145.25.

Remove Ads

Novo Nordisk A/S Trading Down 1.0 %

NYSE NVO opened at $78.14 on Wednesday. The stock has a 50-day simple moving average of $84.61 and a 200 day simple moving average of $104.04. The company has a market capitalization of $350.63 billion, a PE ratio of 23.75, a P/E/G ratio of 0.90 and a beta of 0.42. The company has a current ratio of 0.74, a quick ratio of 0.55 and a debt-to-equity ratio of 0.62. Novo Nordisk A/S has a 12 month low of $73.28 and a 12 month high of $148.15.

Novo Nordisk A/S (NYSE:NVO - Get Free Report) last announced its quarterly earnings results on Wednesday, February 5th. The company reported $0.91 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.88 by $0.03. Novo Nordisk A/S had a return on equity of 84.68% and a net margin of 34.81%. Research analysts forecast that Novo Nordisk A/S will post 3.84 EPS for the current year.

Novo Nordisk A/S Increases Dividend

The firm also recently disclosed a semi-annual dividend, which will be paid on Tuesday, April 8th. Stockholders of record on Monday, March 31st will be given a $0.7874 dividend. This represents a dividend yield of 1.2%. This is a boost from Novo Nordisk A/S's previous semi-annual dividend of $0.51. The ex-dividend date is Monday, March 31st. Novo Nordisk A/S's dividend payout ratio (DPR) is presently 47.72%.

Novo Nordisk A/S Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.